302 related articles for article (PubMed ID: 18925528)
1. Beneficial hematologic effects of daily oral ascorbic acid therapy in ESRD patients with anemia and abnormal iron homeostasis: a preliminary study.
Sirover WD; Siddiqui AA; Benz RL
Ren Fail; 2008; 30(9):884-9. PubMed ID: 18925528
[TBL] [Abstract][Full Text] [Related]
2. Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia.
Attallah N; Osman-Malik Y; Frinak S; Besarab A
Am J Kidney Dis; 2006 Apr; 47(4):644-54. PubMed ID: 16564942
[TBL] [Abstract][Full Text] [Related]
3. Intravenous iron sucrose in Chinese hemodialysis patients with renal anemia.
Li H; Wang SX
Blood Purif; 2008; 26(2):151-6. PubMed ID: 18212498
[TBL] [Abstract][Full Text] [Related]
4. Intravenous ascorbic acid in hemodialysis patients with functional iron deficiency: a clinical trial.
Giancaspro V; Nuzziello M; Pallotta G; Sacchetti A; Petrarulo F
J Nephrol; 2000; 13(6):444-9. PubMed ID: 11132761
[TBL] [Abstract][Full Text] [Related]
5. Erythropoietin requirements: a comparative multicenter study between peritoneal dialysis and hemodialysis.
Coronel F; Herrero JA; Montenegro J; Fernandez C; Gandara A; Conesa J; Rivera MT; Torrente J; Portolés J; Gomez-Martino JR
J Nephrol; 2003; 16(5):697-702. PubMed ID: 14733416
[TBL] [Abstract][Full Text] [Related]
6. Iron supplementation for acute blood loss anemia after coronary artery bypass surgery: a randomized, placebo-controlled study.
Crosby L; Palarski VA; Cottington E; Cmolik B
Heart Lung; 1994; 23(6):493-9. PubMed ID: 7852064
[TBL] [Abstract][Full Text] [Related]
7. The efficacy of iron dextran for the treatment of iron deficiency in hemodialysis patients.
Fishbane S; Lynn RI
Clin Nephrol; 1995 Oct; 44(4):238-40. PubMed ID: 8575123
[TBL] [Abstract][Full Text] [Related]
8. Long-term, low-dose, intravenous vitamin C leads to plasma calcium oxalate supersaturation in hemodialysis patients.
Canavese C; Petrarulo M; Massarenti P; Berutti S; Fenoglio R; Pauletto D; Lanfranco G; Bergamo D; Sandri L; Marangella M
Am J Kidney Dis; 2005 Mar; 45(3):540-9. PubMed ID: 15754276
[TBL] [Abstract][Full Text] [Related]
9. The new rHuEPO alpha (epotin) in the management of anemia of end-stage renal disease in patients on maintenance hemodialysis.
Abbas EE; Afioni N; Al Wakeel J; Bakr MA; Dham R; Donia A; Droubi N; Khidir E; Mathew CM; Mitwali AH; Naga S; Pingle A; Rashed A; Roshdy A; Shaheen F; Shaibani B; Shaibani FM; Shaker DS; Sheiban A; Solieman M
Transplant Proc; 2004; 36(6):1805-11. PubMed ID: 15350482
[TBL] [Abstract][Full Text] [Related]
10. Effects of intravenous ascorbic acid on erythropoiesis and quality of life in unselected hemodialysis patients.
Taji Y; Morimoto T; Okada K; Fukuhara S; Fukui T; Kuwahara T
J Nephrol; 2004; 17(4):537-43. PubMed ID: 15372416
[TBL] [Abstract][Full Text] [Related]
11. The effect of high-flux hemodialysis on renal anemia.
Ayli D; Ayli M; Azak A; Yüksel C; Kosmaz GP; Atilgan G; Dede F; Abayli E; Camlibel M
J Nephrol; 2004; 17(5):701-6. PubMed ID: 15593038
[TBL] [Abstract][Full Text] [Related]
12. The effect of a change in epoetin alfa reimbursement policy on anemia outcomes in hemodialysis patients.
Berns JS; Fishbane S; Elzein H; Lynn RI; Deoreo PB; Tharpe DL; Meisels IS
Hemodial Int; 2005 Jul; 9(3):255-63. PubMed ID: 16191075
[TBL] [Abstract][Full Text] [Related]
13. 12-week clinical effects of erythropoietin espogen in end stage renal patients undergoing hemodialysis.
Thitiarchakul S; Tasanarong A
J Med Assoc Thai; 2007 Apr; 90(4):636-42. PubMed ID: 17487116
[TBL] [Abstract][Full Text] [Related]
14. Effect of intravenous ascorbic acid in hemodialysis patients with anemia and hyperferritinemia.
Shahrbanoo K; Taziki O
Saudi J Kidney Dis Transpl; 2008 Nov; 19(6):933-6. PubMed ID: 18974579
[TBL] [Abstract][Full Text] [Related]
15. Correction of anemia and iron deficiency in vegetarians by administration of ascorbic acid.
Sharma DC; Mathur R
Indian J Physiol Pharmacol; 1995 Oct; 39(4):403-6. PubMed ID: 8582755
[TBL] [Abstract][Full Text] [Related]
16. Administration of exogenous erythropoietin beta affects lipid peroxidation and serum paraoxonase-1 activity and concentration in predialysis patients with chronic renal disease and anaemia.
Marsillach J; Martínez-Vea A; Marcas L; Mackness B; Mackness M; Ferré N; Joven J; Camps J
Clin Exp Pharmacol Physiol; 2007 Apr; 34(4):347-9. PubMed ID: 17324148
[TBL] [Abstract][Full Text] [Related]
17. Endogenous erythropoietin levels and anemia in long-term renal transplant recipients.
Zadrazil J; Horák P; Horcicka V; Zahálková J; Strébl P; Hrubý M
Kidney Blood Press Res; 2007; 30(2):108-16. PubMed ID: 17374961
[TBL] [Abstract][Full Text] [Related]
18. Impact of elevated C-reactive protein levels on erythropoiesis- stimulating agent (ESA) dose and responsiveness in hemodialysis patients.
Bradbury BD; Critchlow CW; Weir MR; Stewart R; Krishnan M; Hakim RH
Nephrol Dial Transplant; 2009 Mar; 24(3):919-25. PubMed ID: 18840893
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of oral versus intravenous ascorbic acid for anaemia in haemodialysis patients.
Chan D; Irish A; Dogra G
Nephrology (Carlton); 2005 Aug; 10(4):336-40. PubMed ID: 16109077
[TBL] [Abstract][Full Text] [Related]
20. Vitamins and quality of life in hemodialysis patients.
Mydlik M; Derzsiová K
J Nephrol; 2008; 21 Suppl 13():S129-33. PubMed ID: 18446746
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
